Details of the Drug

General Information of Drug (ID: DMPRIHK)

Drug Name
Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells
Synonyms
Her2Bi-armed activated T cells (breast cancer), Barbara Ann Karmanos Cancer Institute; Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells (breast cancer); Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells (breast cancer), Barbara Ann Karmanos Cancer Institute
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 2 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D0P7KI

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Erbb2 tyrosine kinase receptor (HER2) TT6EO5L ERBB2_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Breast cancer
ICD Disease Classification 2C60-2C65
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Erbb2 tyrosine kinase receptor (HER2) DTT ERBB2 5.67E-03 -1.26 -2.05
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition), Vol 26, No 15S (May 20 Supplement), 2008: 3034.
2 Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors. J Hematother Stem Cell Res. 2001 Apr;10(2):247-60.